Cargando…

Activity of Cefepime-Zidebactam against Multidrug-Resistant (MDR) Gram-Negative Pathogens

This study compared the activity of cefepime + zidebactam (FEP-ZID) and selected currently available antibacterial agents against a panel of multidrug-resistant (MDR) clinical isolates chosen to provide an extreme challenge for antibacterial activity. FEP–ZID had a very broad and potent in vitro spe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thomson, Kenneth S., AbdelGhani, Sameh, Snyder, James W., Thomson, Gina K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6466586/ https://www.ncbi.nlm.nih.gov/pubmed/30909535 http://dx.doi.org/10.3390/antibiotics8010032

Ejemplares similares

Cefepime-Zidebactam (WCK 5222) Activity Tested against Gram-negative Organisms Causing Bloodstream Infections Worldwide
por: Sader, Helio S, et al.
Publicado: (2017)

675. Efficacy of Human-Simulated Bronchopulmonary Exposures of Cefepime and Zidebactam (WCK 5222) Against Multidrug-Resistant (MDR) Pseudomonas aeruginosa (PSA) in a Neutropenic Murine Pneumonia Model
por: Kidd, James M, et al.
Publicado: (2019)

In Vitro Activity of Two Cefepime-Based Novel Combinations, Cefepime/Taniborbactam and Cefepime/Zidebactam, against Carbapenemase-Expressing Enterobacterales Collected in India
por: Bakthavatchalam, Yamuna Devi, et al.
Publicado: (2023)

In vitro activity of cefepime/zidebactam and cefepime/taniborbactam against aztreonam/avibactam-resistant NDM-like-producing Escherichia coli clinical isolates
por: Le Terrier, Christophe, et al.
Publicado: (2023)

725. WCK 5222 (Cefepime/Zidebactam): An In Vitro Assessment of Activity Compared with Current Dual-Antibiotic Options Against Multidrug-Resistant Pseudomonas aeruginosa
por: Mullane, Elias M, et al.
Publicado: (2019)

2214. Comparison of Cefepime–Zidebactam (WCK 5222), Ceftazidime–Avibactam, and Ceftolozane–Tazobactam Tested Against Gram-Negative Organisms Causing Pneumonia in United States Hospitals in 2018
por: Sader, Helio S, et al.
Publicado: (2019)

CPO Complete, a novel test for fast, accurate phenotypic detection and classification of carbapenemases
por: Thomson, Gina K., et al.
Publicado: (2019)

The effect of varying multidrug-resistence (MDR) definitions on rates of MDR gram-negative rods
por: Wolfensberger, Aline, et al.
Publicado: (2019)

1598. Antimicrobial Activity of the Novel β-Lactam Enhancer Combination Cefepime–Zidebactam (WCK-5222) Tested Against Gram-Negative Bacteria Isolated in United States Medical Centers from Patients with Bloodstream Infections
por: Castanheira, Mariana, et al.
Publicado: (2019)

1063. ARGONAUT-V: Susceptibility of Multidrug-Resistant (MDR) Pseudomonas aeruginosa to Cefepime-Taniborbactam
por: Mack, Andrew R, et al.
Publicado: (2021)

Bicyclomycin Activity against Multidrug-Resistant Gram-Negative Pathogens
por: Wang, Weijie, et al.
Publicado: (2022)

Molecular Characterization of WCK 5222 (Cefepime/Zidebactam)-Resistant Mutants Developed from a Carbapenem-Resistant Pseudomonas aeruginosa Clinical Isolate
por: Pan, Xiaolei, et al.
Publicado: (2022)

1181. Use of the Combination Antibiogram in the Era of MDR Gram-Negative Pathogens
por: Klinker, Kenneth, et al.
Publicado: (2018)

1336. Assessment of the In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) Against Carbapenems-Resistant Acinetobacter baumannii (CR-ACBN) in the Neutropenic Murine Thigh Infection Model
por: Abuhussain, Safa Almarzoky, et al.
Publicado: (2018)

Activity of ertapenem/zidebactam (WCK 6777) against problem Enterobacterales
por: Mushtaq, Shazad, et al.
Publicado: (2022)

Predatory Bacteria: A Potential Ally against Multidrug-Resistant Gram-Negative Pathogens
por: Kadouri, Daniel E., et al.
Publicado: (2013)

CXC Chemokines Exhibit Bactericidal Activity against Multidrug-Resistant Gram-Negative Pathogens
por: Crawford, Matthew A., et al.
Publicado: (2017)

Zidebactam restores sulbactam susceptibility against carbapenem-resistant Acinetobacter baumannii isolates
por: Cedano, Jose, et al.
Publicado: (2022)

The “Old” and the “New” Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How
por: Karaiskos, Ilias, et al.
Publicado: (2019)

719. Cefiderocol Retains Anti-Biofilm Activity in MDR Gram-Negative Pathogens
por: Pybus, Christine A, et al.
Publicado: (2019)

Fosfomycin in infections caused by multidrug-resistant Gram-negative pathogens
por: Ruiz Ramos, Jesús, et al.
Publicado: (2019)

Baicalein Resensitizes Multidrug-Resistant Gram-Negative Pathogens to Doxycycline
por: Wang, Yuhang, et al.
Publicado: (2023)

A Novel Topical Combination Ointment with Antimicrobial Activity against Methicillin-Resistant Staphylococcus aureus, Gram-Negative Superbugs, Yeasts, and Dermatophytic Fungi
por: Thomson, Kenneth S., et al.
Publicado: (2016)

In vitro Activity of Fosfomycin, Alone and Combined with Cefepime and Meropenem, Against Carbapenemase-Producing Gram-Negative Bacteria
por: Wiederhold, Nathan P, et al.
Publicado: (2017)

Cefiderocol Retains Antibiofilm Activity in Multidrug-Resistant Gram-Negative Pathogens
por: Pybus, Christine A., et al.
Publicado: (2021)

Treatment of Infections Due to MDR Gram-Negative Bacteria
por: Bassetti, Matteo, et al.
Publicado: (2019)

Molecular characterization of multidrug-resistant Gram-negative pathogens in three tertiary hospitals in Cairo, Egypt
por: El-Kholy, Amani A., et al.
Publicado: (2020)

685. An In Vitro Investigation of WCK 5222 (Cefepime/Zidebactam) and Currently Available Combination Antibiotic Regimens Against Enterobacteriaceae That Co-express Serine-β-Lactamase (SBL) and Metallo-β-Lactamase (MBL) Enzymes
por: Avery, Lindsay M, et al.
Publicado: (2019)

Engineered Endolysin-Based “Artilysins” To Combat Multidrug-Resistant Gram-Negative Pathogens
por: Briers, Yves, et al.
Publicado: (2014)

2122. In Vitro Activity of Cefepime-Taniborbactam Against Clinically Significant Gram-Negative Bacteria Isolated from Patients with Cancer
por: Gerges, Bahgat Z, et al.
Publicado: (2023)

Early appropriate diagnostics and treatment of MDR Gram-negative infections
por: Bassetti, Matteo, et al.
Publicado: (2022)

Ever-Adapting RND Efflux Pumps in Gram-Negative Multidrug-Resistant Pathogens: A Race against Time
por: Zwama, Martijn, et al.
Publicado: (2021)

Impact of COVID-19 pandemic on multidrug resistant gram positive and gram negative pathogens: A systematic review
por: Abubakar, Usman, et al.
Publicado: (2023)

Defining multidrug resistance in Gram-negative bacilli
por: Kumar, V. Anil, et al.
Publicado: (2015)

Phentolamine Significantly Enhances Macrolide Antibiotic Antibacterial Activity against MDR Gram-Negative Bacteria
por: Cui, Ze-Hua, et al.
Publicado: (2023)

In Vitro Activity of Cefepime-Enmetazobactam against Gram-Negative Isolates Collected from U.S. and European Hospitals during 2014–2015
por: Morrissey, Ian, et al.
Publicado: (2019)

Antibiotic synergy testing for multidrug-resistant Gram-negative pathogens in a Greek ICU
por: Douka, E, et al.
Publicado: (2015)

A synthetic lipopeptide targeting top-priority multidrug-resistant Gram-negative pathogens
por: Roberts, Kade D., et al.
Publicado: (2022)

Squalamine: An Appropriate Strategy against the Emergence of Multidrug Resistant Gram-Negative Bacteria?
por: Salmi, Chanaz, et al.
Publicado: (2008)

An amphipathic peptide with antibiotic activity against multidrug-resistant Gram-negative bacteria
por: Elliott, Alysha G., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_m2652mlr0n7knab619agemmof4